Moberg Pharma ABFRA:MB8 +2.28%59 Current Ratio is 13.13 as of Mar. 2026, which is 138% above its 10-year median of 5.51. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.07. The stock has 1 warning sign investors should review. Among 995 Drug Manufacturers companies, Moberg Pharma AB ranks better than 95.58% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Moberg Pharma AB's current ratio for the quarter that ended in Mar. 2026 was 13.13.
Moberg Pharma AB has a current ratio of 13.13. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Moberg Pharma AB's Current Ratio or its related term are showing as below:
FRA:MB8'
s Current Ratio Range Over the Past 10 Years
Min: 1.28 Med: 5.51 Max: 22.52
Current: 13.12
During the past 13 years, Moberg Pharma AB's highest Current Ratio was 22.52. The lowest was 1.28. And the median was 5.51.
FRA:MB8's Current Ratio is ranked better than 95.58% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:MB8: 13.12
Moberg Pharma AB (FRA:MB8) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Moberg Pharma AB Current Ratio Related Terms
Moberg Pharma AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (FRA:MB8) has a Current Ratio of 13.13 as of Mar. 2026. This is 138% above median its historical median of 5.51. Over the past decade, Moberg Pharma AB's Current Ratio has ranged from 1.28 to 22.52. According to the industry distribution chart, Moberg Pharma AB ranks #44 out of 995 companies in the Drug Manufacturers industry, placing it in the top 4.4%.
Is Moberg Pharma AB's Current Ratio too high?
Moberg Pharma AB's current Current Ratio of 13.13 is 138% above median its 10-year median of 5.51. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 22.52. The Drug Manufacturers industry median Current Ratio is 2.00. Moberg Pharma AB's value of 13.13 is 556.5% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #44 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #44 out of 995 companies for Current Ratio. This places Moberg Pharma AB in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Moberg Pharma AB's value of 13.13 is 556.5% above this benchmark. Historically, Moberg Pharma AB's own Current Ratio has ranged from 1.28 to 22.52 over the past decade. While the company's 10-year median is 5.51 vs. the industry median of 2.00, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current Current Ratio of 13.13 is 556.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Current Ratio is 13.13, which is 138% above median its own 10-year median of 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Current Ratio of 13.13. The stock's GF Value™ is €1.07, compared to a current price of €0.81 — trading 24.6% below its estimated fair value. The current Current Ratio is 13.13, which is 138% above median its 10-year median of 5.51 and 556.5% above the Drug Manufacturers industry median of 2.00. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Current Ratio is 13.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.81 is trading 24.6% below its estimated GF Value™ of €1.07.
Key valuation signals for FRA:MB8:
Current Ratio: 13.13 (138% above median its 10-year median of 5.51)
GF Value™: €1.07 vs. price of €0.81 (24.6% below fair value)
Industry Position: 556.5% above the Drug Manufacturers median (#44 of 995)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
